An interventional study of Electric Blanket in Blood Pressure Check (Hypertension Screening), Heart Rate and Aldosterone Disorder, sponsored by Jinan University Guangzhou. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 30 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-18.
Sponsored by Jinan University Guangzhou · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 410 studies in Hypertension with a site in China — 124 open to participants now, 148 under way, 12 of them phase 3. Hypertension · China.
Among the 410 studies in Hypertension with a site in China, this one is the 263rd largest by planned enrollment of the 308 interventional ones that give a count, is one of 30 that started in 2024, is one of 146 with no phase, reaches primary completion later than 15 of the 147 other live ones, and was the 305th registered.
6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.
Browse Hypertension studies →124 of the 410 studies in Hypertension with a site in China are open now. Recruiting first, the newest first:
Shandong Suncadia Medicine Co., Ltd. · Sites in China
Ages 18–80
Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 18+
AstraZeneca · Sites in China
Ages 18+
Pulnovo Medical, Inc. · Sites in China, United States
Ages 18–85
China Medical University, China · Sites in China
Ages 50–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.
This study: 18 Years to 30 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
410 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 23 · Phase 3 50 · Phase 4 76
First in 1998; this study’s year is marked. 30 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 253 across the 308 interventional studies, 1,000 across the 102 observational. Of the 161 that completed or were terminated, 22 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
103 of 410 have an industry lead sponsor. The 10 most frequent:
Jinan University Guangzhou is the lead sponsor of 14 studies on the registry; 2 are open to participants now.
Jinan University Guangzhou has 1 study filed under Hypertension — fewer than ten, so there is no comparison to draw.
47 of the studies in Hypertension with a site in China that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT06948422Phase 3Eli Lilly and CompanyA Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening) | 2027-09 |
| NCT06948435Phase 3Eli Lilly and CompanyA Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 | 2027-09 |
| NCT06952530Phase 3Eli Lilly and CompanyA Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2 | 2027-09 |
| NCT07241338Jing LiuSacubitril/Allisartan for Hypertensive Patients With Overweight or Obesity | 2026-11 |
Add all 47 to your calendar (.ics) → With an account.
Among the 410 studies in Hypertension with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This will be a crossover controlled trial designed to recruit 40 participants, who will be divided into two groups of 20 subjects each. The participants will be randomly assigned to either Group A or Group B. Group A will receive the sleep electric blanket intervention for a period of 7 days, while Group B will serve as the control group without any additional intervention. After the intervention period, there will be a washout period of 7 days to ensure that any effects of the intervention have subsided before the crossover.
Following the washout period, the groups will switch roles: Group B will then receive the sleep electric blanket intervention, and Group A will become the control group. This second phase will also last for 7 days, preceded and followed by the same assessment procedures as the initial phase. This design will allow for a comparison of the intervention's effects against a control period within the same group of participants, enhancing the study's internal validity.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be randomized into groups A and B. When the subject's group cohort undergoes the intervention phase (as opposed to the control phase), they will receive a 7-day, 8-hour intervention with an electric blanket set at +5±1°C above room temperature.
Device: Electric Blanket
Participants will be randomized into groups A and B. There will be no additional sleep temperature intervention while the group is in the control period.
Participants were randomized to groups A and B. When the subject\'s group cohort went through the intervention phase (instead of the control phase), they received a 7-day, 8-hour intervention with an electric blanket +5±1°C above room temperature.
Blood pressure
Including systolic blood pressure (SBP) and diastolic blood pressure (DBP), Includes office blood pressure, home blood pressure and ambulatory blood pressure.
Time frame: 1month
Plan to share: Yes — The experiment will be made public upon completion with the publication of the related paper, sharing: contact the researcher for a copy.
Supporting information: Study protocol, Informed consent form
No publications or documents are linked to this record.
Start is estimated for Oct 2024; primary completion for Jan 2025, 3 months later.
Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 3 months is below that.
Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Jinan University Guangzhou